Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K040359
    Date Cleared
    2004-03-19

    (35 days)

    Product Code
    Regulation Number
    864.5425
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The intended use to HemosIL Special Test Controls Level 1 & 2 is being expanded with the addition of value assignments for chromogenic Factor VIII tests (Levels 1 and 2) and clotting factor assays (Level 2 only). There are no changes in product formulation or alterations in the fundamental scientific technology introduced with the new value assignments.

    HemosIL Special Test Controls Level 1 & 2 is labeled:

    • For the quality control in the abnormal range of the chromogenic tests (Antithrombin, Plasminogen, Plasmin Inhibitor, Protein C and Factor VIII) and Free Protein S assay performed on the IL Coagulation Systems.
    • For the Quality Control of von Willebrand Factor assay in the normal (Level 1) and abnormal range (Level 2) on the IL Coagulation Systems.
    • For the Quality Control of factor assays (clotting) in the abnormal range (Level 2) on the IL Coagulation Systems.
    Device Description

    The intended use to HemosIL Special Test Controls Level 1 & 2 is being expanded with the addition of value assignments for chromogenic Factor VIII tests (Levels 1 and 2) and clotting factor assays (Level 2 only). There are no changes in product formulation or alterations in the fundamental scientific technology introduced with the new value assignments.

    AI/ML Overview

    The provided text describes the 510(k) summary for the HemosIL Special Test Controls Level 1 & 2, focusing on the expanded indications for use for chromogenic Factor VIII tests and clotting factor assays. It details the performance data that supports the substantial equivalence of the device.

    Here's a breakdown of the requested information based on the provided text:

    1. A table of acceptance criteria and the reported device performance

    The document does not explicitly state "acceptance criteria" as a separate, defined threshold. Instead, it presents the "reported device performance" in terms of "Mean (%)" and "Within-Run %CV" for various assays. The implication is that these reported values are deemed acceptable for the expanded indications, as the device received 510(k) clearance, signifying substantial equivalence to a legally marketed predicate device.

    Reagent (Expanded Indication)InstrumentLevelReported Mean (%) (n=32)Reported Within-Run %CVAcceptance Criteria (Implied)
    ELECTRACHROME Factor VIIIACL 9000Level 167.53.30Not explicitly stated
    ELECTRACHROME Factor VIIIACL 9000Level 237.93.53Not explicitly stated
    HemosIL Factor IIACL Classic33.04.31Not explicitly stated
    HemosIL Factor IIACL Futura/ACL Advance30.88.77Not explicitly stated
    Deficient Plasma (Factor II)ACL 900034.13.16Not explicitly stated
    HemosIL Factor VACL Classic33.62.50Not explicitly stated
    HemosIL Factor VACL Futura/ACL Advance37.13.15Not explicitly stated
    Deficient Plasma (Factor V)ACL 900036.52.27Not explicitly stated
    HemosIL Factor VIIACL Classic30.53.09Not explicitly stated
    HemosIL Factor VIIACL Futura/ACL Advance34.86.76Not explicitly stated
    Deficient Plasma (Factor VII)ACL 900033.13.53Not explicitly stated
    HemosIL Factor VIIIACL Classic33.75.54Not explicitly stated
    HemosIL Factor VIIIACL Futura/ACL Advance36.15.52Not explicitly stated
    Deficient Plasma (Factor VIII)ACL 900032.46.93Not explicitly stated
    HemosIL Factor IXACL Classic34.83.23Not explicitly stated
    HemosIL Factor IXACL Futura/ACL Advance34.110.07Not explicitly stated
    Deficient Plasma (Factor IX)ACL 900034.27.45Not explicitly stated
    HemosIL Factor XACL Classic31.61.65Not explicitly stated
    HemosIL Factor XACL Futura/ACL Advance32.82.12Not explicitly stated
    Deficient Plasma (Factor X)ACL 900034.32.13Not explicitly stated
    HemosIL Factor XIACL Classic28.52.99Not explicitly stated
    HemosIL Factor XIACL Futura/ACL Advance30.013.24Not explicitly stated
    Deficient Plasma (Factor XI)ACL 900030.24.34Not explicitly stated
    HemosIL Factor XIIACL Classic34.17.22Not explicitly stated
    HemosIL Factor XIIACL Futura/ACL Advance29.77.40Not explicitly stated
    Deficient Plasma (Factor XII)ACL 900034.32.61Not explicitly stated

    2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

    • Sample size for the test set: The "n=32" is explicitly stated for the "Mean (%)" in the performance tables, indicating 32 measurements were taken for each reported value.
    • Data Provenance: The document does not specify the country of origin or whether the data was retrospective or prospective.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

    This information is not provided in the document. The study involves quality control materials for in vitro coagulation studies, where "ground truth" would typically refer to the target or reference values established for the control material itself, rather than expert interpretation of patient data.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

    This information is not applicable and therefore not provided. The study focuses on the analytical performance (mean and precision) of the control material on specific instruments, not on the interpretation of results by multiple human readers.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    An MRMC comparative effectiveness study was not performed, nor is it relevant to this type of device (in vitro diagnostic quality control material). This device is a control material for laboratory tests, not an AI-powered diagnostic tool requiring human interpretation.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    This concept is not applicable to the device. The "device" itself is a control material, not an algorithm. The performance data presented is the "standalone" performance of the control material when assayed on various laboratory instruments.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

    The "ground truth" for quality control materials refers to the assigned or target values for the analytes within the control. This is typically established through rigorous analytical methods, often characterized through inter-laboratory studies or traceability to reference materials. The document states that the intended use is being expanded with the addition of "value assignments," implying such a characterization was performed, but the specific type of "ground truth" establishment (e.g., a specific reference method or consensus process) is not detailed here.

    8. The sample size for the training set

    This is not applicable as the device is a quality control material and not an algorithm requiring a training set.

    9. How the ground truth for the training set was established

    This is not applicable as the device does not involve a training set.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1